Management of advanced breast cancer with the epothilone B analog, ixabepilone
William GradisharRobert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: Despite the activity of standard chemotherapies in advanced breast cancer, disease progression remains inevitable. Most patients exposed to anthracyclines and t...
Main Author: | William Gradishar |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-06-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/management-of-advanced-breast-cancer-with-the-epothilone-b-analog-ixab-a3225 |
Similar Items
-
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
by: Patrick A Ott, et al.
Published: (2010-01-01) -
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01) -
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
by: Massimo Cristofanilli
Published: (2012-01-01) -
NEW ADVANCES IN THE TREATMENT OF BREAST CANCER: THE ROLE EPOTHILONES
by: T. Y. SEMIGLAZOVA, et al.
Published: (2017-06-01)